Edition:
United States

Akari Therapeutics PLC (AKTX.OQ)

AKTX.OQ on NASDAQ Stock Exchange Capital Market

2.33USD
21 Feb 2018
Change (% chg)

-- (--)
Prev Close
$2.33
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
64,157
52-wk High
$22.16
52-wk Low
$2.06

Chart for

About

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal... (more)

Overall

Beta: -7.64
Market Cap(Mil.): $35.55
Shares Outstanding(Mil.): 0.15
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 189.80 16.52
EPS (TTM): -- -- --
ROI: -- -0.65 36.19
ROE: -- -3.21 17.38

BRIEF-Akari Therapeutics Says Mid-stage Trial Of Coversin In Patients With Rare Blood Disease PNH Successful

* AKARI THERAPEUTICS ANNOUNCES PHASE II COBALT TRIAL OF COVERSIN™ IN PATIENTS WITH PNH MET THE PRIMARY ENDPOINT

Dec 08 2017

BRIEF-Akari Therapeutics proposes public offering of ADS

* Akari Therapeutics announces proposed public offering of American Depositary Shares Source text for Eikon: Further company coverage:

Oct 17 2017

BRIEF-Akari Therapeutics announces further clinical progress

* Akari Therapeutics - 3 additional patients have been enrolled in ongoing Phase II Cobalt clinical trial of Coversin in patients with PNH​

Oct 11 2017

BRIEF-Akari ‍plans to advance its lead drug, Coversin towards Phase III clinical studies in paroxysmal nocturnal hemoglobinuria in Q1 2018​

* ‍plans to advance its lead drug, Coversin towards Phase III clinical studies in paroxysmal nocturnal hemoglobinuria in Q1 2018​

Sep 21 2017

Earnings vs. Estimates